FibroGen, Inc. Announces Promising Preliminary Data from an Open-label Phase 2 Study to Evaluate the Safety and Efficacy of FG-3019 in Individuals With Idiopathic Pulmonary Fibrosis (IPF) and Provides Program Update

Published: May 03, 2012

SAN FRANCISCO--(BUSINESS WIRE)-- FibroGen, Inc., today announced expansion of an ongoing open-label Phase 2 study to evaluate the safety, tolerability, and efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), in individuals with idiopathic pulmonary fibrosis (IPF). The company’s decision to add a second, higher dose group is based on promising preliminary data from the first dose group as well as dose-escalation data from other clinical trials of FG-3019 indicating that higher doses of FG-3019 appear to be associated with a more robust biological and clinical response. FibroGen has also decided to add on another year of FG-3019 therapy for patients in the first dose group who are exhibiting stable or improved lung function in order to evaluate whether the observed maintenance of lung function continues.

Back to news